Skip to Content

Busulfan Disease Interactions

There are 4 disease interactions with busulfan:

Major

Busulfan (applies to busulfan) infections

Major Potential Hazard, High plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Busulfan can induce severe and prolonged myelosuppression. Treatment with busulfan should not be initiated in patients with known infectious diseases. All patients should be instructed to immediately report any signs or symptoms suggesting infection such as fever, sore throat, or local infection during therapy with busulfan. Close clinical monitoring of hematopoietic function is recommended.

References

  1. "Product Information. Myleran (busulfan)." Prasco Laboratories, Cincinnati, OH.
Major

Busulfan (applies to busulfan) myelosuppression

Major Potential Hazard, High plausibility. Applicable conditions: Bone Marrow Depression/Low Blood Counts, Fever, Bleeding

Busulfan induces severe and prolonged myelosuppression at the recommended dosage. Hematopoietic progenitor cell transplantation is required to prevent potentially fatal complications of the prolonged myelosuppression. It is recommended to closely monitor complete blood counts, including white blood cell differentials, and quantitative platelet counts daily during treatment and until engraftment is demonstrated. Extreme caution should be exercised if busulfan is administered in patients whose bone marrow reserve may be compromised by prior irradiation or chemotherapy or whose marrow function is recovering from previous cytotoxic therapy. Patients should be instructed to immediately report any signs or symptoms suggesting bone marrow suppression, such as fever, sore throat, local infection, bleeding, or symptoms of anemia.

References

  1. Fernandez LA, Zayed E "Busulfan-induced sideroblastic anemia." Am J Hematol 28 (1988): 199-200
  2. "Product Information. Myleran (busulfan)." Prasco Laboratories, Cincinnati, OH.
Moderate

Busulfan (applies to busulfan) cardiac tamponade

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Thalassemia

Cardiac tamponade during high dose busulfan therapy combined with cyclophosphamide has been reported in pediatric patients with thalassemia. Abdominal pain and vomiting may precede the tamponade. Cardiac tamponade can result in death and therapy with busulfan should be administered cautiously to patients with thalassemia.

References

  1. "Product Information. Myleran (busulfan)." Prasco Laboratories, Cincinnati, OH.
Moderate

Busulfan (applies to busulfan) seizure disorders

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Head Injury, Seizures

Seizures have been reported in patients receiving high doses of busulfan. Therapy with busulfan should be administered cautiously to patients with a history of a seizure disorder or head trauma or who are receiving other potentially epileptogenic drugs.

References

  1. Hassan M, Oberg G, Bjorkholm M, Ehrsson H "Influence of anticonvulsant prophylaxis on high-dose busulphan pharmacokinetics (Meeting abstract)." 18th International Congress of Chemotherapy. June 27-July 2, 1993, Stoc (1993): 388
  2. Sureda A, Perez de Oteyza J, Garcia Larana J, Odriozola J "High-dose busulfan and seizures." Ann Intern Med 111 (1989): 543-4
  3. Marcus RE, Goldman JM "Convulsions due to high-dose busulphan." Lancet 2 (1984): 1463
  4. "Product Information. Myleran (busulfan)." Prasco Laboratories, Cincinnati, OH.
  5. Martell RW, Sher C, Jacobs P, Monteagudo F "High-dose busulfan and myoclonic epilepsy." Ann Intern Med 106 (1987): 173
  6. Murphy CP, Harden EA, Thompson JM "Generalized seizures secondary to high-dose busulfan therapy." Ann Pharmacother 26 (1992): 30-1
View all 6 references

Busulfan drug interactions

There are 230 drug interactions with busulfan

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.